Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin
Phase 1 Completed
99 enrolled 11 charts
NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922)
Phase 1 Completed
65 enrolled 38 charts
Topotecan by Intracerebral Clysis for Recurrent Primary Malignant Brain Tumors
Phase 1 Completed
16 enrolled 14 charts
Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor
Phase 1 Completed
25 enrolled
DFMO
Phase 1 Completed
30 enrolled
Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma
Phase 1 Completed
150 enrolled 9 charts
Crizotinib and Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma
Phase 1 Completed
46 enrolled 24 charts
Topotecan Hydrochloride and Doxorubicin Hydrochloride in Treating Relapsed or Refractory Small Cell Lung Cancer
Phase 1 Completed
22 enrolled
Cabozantinib With Topotecan-Cyclophosphamide
Phase 1 Completed
12 enrolled
Chronic Convection Enhanced Delivery of Topotecan
Phase 1 Completed
5 enrolled
Evaluate Oral Topotecan With HM30181A Monotherapy in Patients With Advanced Malignancies
Phase 1 Completed
10 enrolled
AflacST1402
Phase 1 Completed
13 enrolled
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
Phase 1 Completed
131 enrolled
Topotecan, High-Dose Cyclophosphamide, Carboplatin, and an Autologous Peripheral Blood Cell Transplant in Treating Patients With Recurrent Ovarian Cancer or Primary Peritoneal Cancer
Phase 1 Completed
48 enrolled
Topotecan and Vinorelbine in Treating Patients With Recurrent Lung Cancer
Phase 1 Completed
18 enrolled
Topotecan, Cisplatin, and Radiation Therapy in Treating Patients With Advanced Cervical Cancer
Phase 1 Completed
18 enrolled
Topotecan Pharmacokinetic Characterization Study
Phase 1 Completed
15 enrolled
A Study To Determine If Two Different Versions Of Topotecan Have The Same Potency In Patients With Advanced Solid Tumors
Phase 1 Completed
107 enrolled
A Phase I Topotecan Study in Subjects With Cancer and Impaired Renal Function
Phase 1 Completed
59 enrolled
Open-label Study of Topotecan and Pazopanib in Advanced Solid Tumors
Phase 1 Completed
68 enrolled
Bortezomib and Topotecan Hydrochloride in Treating Patients With Advanced Solid Tumors
Phase 1 Completed
54 enrolled
A Pilot Trial of Oral Topotecan for the Treatment of Refractory Advanced Solid Neoplasms Expressing HIF-1a
Phase 1 Completed
16 enrolled
Safety Study of ABT-888 Plus Topotecan Hydrochloride to Treat Patients With Solid Tumors and Lymphomas
Phase 1 Completed
31 enrolled
Sirolimus With Cyclophosphamide and Topotecan for Pediatric/Adolescent Relapsed and Refractory Solid Tumors
Phase 1 Completed
21 enrolled
A Bioequivalence Study of Two Oral Formulations of Topotecan in Patients With Advanced Solid Tumors
Phase 1 Completed
1 enrolled
Phase I Trial of Oral Metronomic Topotecan and Oral Pazopanib to Treat Recurrent/Persistent Gynecologic Tumors
Phase 1 Completed
33 enrolled 7 charts
UCN-01 and Topotecan in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer
Phase 1 Completed
33 enrolled
A Study Evaluating BSI-201 in Combination With Chemotherapeutic Regimens in Subjects With Advanced Solid Tumors
Phase 1 Completed
136 enrolled
Sorafenib and Topotecan in Refractory/Recurrent Pediatric Malignancies
Phase 1 Completed
13 enrolled
Phase I Study of Weekly Topotecan in Combination With Sorafenib in Treatment of Relapsed Small Cell Lung Cancer
Phase 1 Completed
16 enrolled
Combination Chemotherapy and Autologous Peripheral Stem Cell Transplant in Treating Patients With Stage III, Stage IV, or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
Phase 1 Completed
8 enrolled
Induction Chemotherapy Using Cyclophosphamide and Topotecan in Treating Patients Who Are Undergoing Autologous Peripheral Stem Cell Transplantation for Newly Diagnosed or Progressive Neuroblastoma
Phase 1 Completed
31 enrolled
Study of the Weekly Oral RAD001 in Combination With Oral Topotecan in Patients With Advanced or Recurrent Endometrial Cancers
Phase 1 Completed
10 enrolled
A Phase I Study of Oral Topotecan as a Radiosensitizing Agent in Patients With Rectal Carcinoma
Phase 1 Completed
31 enrolled
Combination Chemotherapy in Treating Young Patients With Relapsed or Refractory Acute Leukemia
Phase 1 Completed
23 enrolled
Ph I Oral Topotecan and Temozolomide for Patients With Malignant Gliomas
Phase 1 Completed
62 enrolled
A Phase I Study of CCI-779 (Temsirolimus) in Combination With Topotecan in Patients With Gynecologic Malignancies
Phase 1 Completed
15 enrolled
Combination Chemotherapy With or Without Biological Therapy in Treating Patients With Refractory Solid Tumor or Lymphoma
Phase 1 Completed
17 enrolled
Topotecan in Treating Patients With Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
Phase 1 Completed
20 enrolled
Paclitaxel Plus Topotecan in Treating Patients With Solid Tumors
Phase 1 Completed
20 enrolled
Topotecan Plus Etoposide in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer
Phase 1 Completed
24 enrolled
Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cancer
Phase 1 Completed
Topotecan in Treating Patients With Gynecologic Cancer That Cannot Be Removed by Surgery
Phase 1 Completed
26 enrolled
Chemotherapy in Treating Patients With Recurrent Malignant Glioma
Phase 1 Completed
36 enrolled
Study of Temsirolimus, Topotecan, and Bortezomib
Phase 1 Completed
80 enrolled
Radiation Therapy Plus Topotecan in Treating Patients With Non-small Cell Lung Cancer
Phase 1 Completed
20 enrolled
Topotecan in Treating Children With Refractory Leukemia
Phase 1 Completed
3 enrolled
A Dose Finding Phase I Trial of the Combination of Topotecan and PS-341, a Novel Proteasome Inhibitor, in Advanced Malignancies
Phase 1 Completed
25 enrolled
Paclitaxel, Cisplatin, and Topotecan With or Without Filgrastim in Treating Patients With Newly Diagnosed Stage III or Stage IV Epithelial Ovarian Cancer
Phase 1 Completed
30 enrolled
R115777 Plus Topotecan in Treating Patients With Advanced Solid Tumors
Phase 1 Completed